- $598.41m
- $376.29m
- $1.56bn
- 47
- 51
- 26
- 37
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,435 | 2,494 | 2,756 | 1,929 | 1,561 |
Cost of Revenue | |||||
Gross Profit | 288 | 571 | 624 | 443 | 314 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,497 | 2,397 | 2,645 | 1,902 | 1,705 |
Operating Profit | -62.4 | 96.7 | 111 | 27 | -144 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -61.8 | 96.5 | 123 | -33.9 | -266 |
Provision for Income Taxes | |||||
Net Income After Taxes | -62.9 | 95.1 | 172 | -35.2 | -308 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -121 | 58.7 | 369 | -35.2 | -308 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -121 | 51.5 | 351 | -36.9 | -308 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.79 | 1.91 | 3.57 | -0.833 | -6.53 |